IVF
INVO Fertility, Inc.
Medical - Devices
Market Cap$2M
5Y Perf.-100.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
IVF vs HOLX vs NTRA vs INMD
Revenue, margins, valuation, and 5-year total return — side by side.
HOLX
Hologic, Inc.
Medical - Instruments & Supplies
Market Cap$16.97B
5Y Perf.+42.6%
NTRA
Natera, Inc.
Medical - Diagnostics & Research
Market Cap$27.53B
5Y Perf.+343.0%
INMD
InMode Ltd.
Medical - Devices
Market Cap$884M
5Y Perf.-4.8%
IVF vs HOLX vs NTRA vs INMD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IVF | HOLX | NTRA | INMD |
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Diagnostics & Research | Medical - Devices |
| Market Cap | $2M | $16.97B | $27.53B | $884M |
| Revenue (TTM) | $7M | $4.13B | $2.50B | $375M |
| Net Income (TTM) | $-29M | $544M | $-226M | $87M |
| Gross Margin | 39.2% | 52.8% | 65.2% | 77.8% |
| Operating Margin | -370.2% | 17.5% | -13.0% | 21.3% |
| Forward P/E | — | 17.2x | — | 10.3x |
| Total Debt | $10M | $2.63B | $214M | $13M |
| Cash & Equiv. | $741K | $1.96B | $1.08B | $303M |
IVF vs HOLX vs NTRA vs INMD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IVF
HOLX
NTRA
INMD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| INVO Fertility, Inc. (IVF) | 100 | 0.0 | -100.0% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
| Natera, Inc. (NTRA) | 100 | 443.0 | +343.0% |
| InMode Ltd. (INMD) | 100 | 95.2 | -4.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IVF vs HOLX vs NTRA vs INMD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: INMD leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Hologic, Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. IVF also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
IVF
INVO Fertility, Inc.
The Growth Play
IVF is the clearest fit if your priority is growth exposure.
- Rev growth 116.3%, EPS growth 55.2%, 3Y rev CAGR 16.2%
- 116.3% revenue growth vs INMD's -6.2%
Best for: growth exposure
HOLX
Hologic, Inc.
The Income Pick
HOLX is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- beta 0.45
- Beta 0.45, current ratio 3.75x
- Beta 0.45 vs IVF's 1.29, lower leverage
- +35.3% vs IVF's -99.3%
Best for: income & stability and defensive
NTRA
Natera, Inc.
The Long-Run Compounder
NTRA is the clearest fit if your priority is long-term compounding.
- 18.3% 10Y total return vs HOLX's 124.3%
Best for: long-term compounding
INMD
InMode Ltd.
The Defensive Pick
INMD carries the broadest edge in this set and is the clearest fit for sleep-well-at-night.
- Lower volatility, beta 1.00, Low D/E 1.9%, current ratio 9.88x
- Better valuation composite
- 23.3% margin vs IVF's -417.0%
- 11.8% ROA vs IVF's -99.6%, ROIC 13.5% vs -42.2%
Best for: sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IVF | 116.3% revenue growth vs INMD's -6.2% |
| Value | INMD | Better valuation composite |
| Quality / Margins | INMD | 23.3% margin vs IVF's -417.0% |
| Stability / Safety | HOLX | Beta 0.45 vs IVF's 1.29, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | HOLX | +35.3% vs IVF's -99.3% |
| Efficiency (ROA) | INMD | 11.8% ROA vs IVF's -99.6%, ROIC 13.5% vs -42.2% |
IVF vs HOLX vs NTRA vs INMD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
FY 2025
IVF vs HOLX vs NTRA vs INMD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLINMDLAGGINGIVF
Who Leads Where
INMD leads in 3 of 6 categories
NTRA leads 1 • HOLX leads 1 • IVF leads 0
Explore the data ↓IVFINVO Fertility, Inc.
0leads
NTRANatera, Inc.
1leads
HOLXHologic, Inc.
1leads
INMDInMode Ltd.
3leads
6 Total Categories
CATEGORYLEADERvs HOLXvs NTRAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
INMD3/6
Valuation MetricsMultiples, price ratios, and targets
INMD3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
INMD5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
NTRA4/6
Risk & VolatilityBeta, volatility, and downside exposure
HOLX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
INMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HOLX is the larger business by revenue, generating $4.1B annually — 594.2x IVF's $7M. INMD is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to IVF's -4.2%. On growth, NTRA holds the edge at +38.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | IVFINVO Fertility, I… | HOLXHologic, Inc. | NTRANatera, Inc. | INMDInMode Ltd. |
|---|---|---|---|---|
| RevenueTrailing 12 months | $7M | $4.1B | $2.5B | $375M |
| EBITDAEarnings before interest/tax | -$25M | $974M | -$333M | $81M |
| Net IncomeAfter-tax profit | -$29M | $544M | -$226M | $87M |
| Free Cash FlowCash after capex | -$8M | $1000M | $74M | $91M |
| Gross MarginGross profit ÷ Revenue | +39.2% | +52.8% | +65.2% | +77.8% |
| Operating MarginEBIT ÷ Revenue | -3.7% | +17.5% | -13.0% | +21.3% |
| Net MarginNet income ÷ Revenue | -4.2% | +13.2% | -9.0% | +23.3% |
| FCF MarginFCF ÷ Revenue | -111.9% | +24.2% | +3.0% | +24.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.6% | +2.5% | +38.8% | +5.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +94.9% | -9.2% | -20.0% | -30.8% |
INMD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
INMD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 9.8x trailing earnings, INMD trades at a 68% valuation discount to HOLX's 30.5x P/E. On an enterprise value basis, INMD's 6.9x EV/EBITDA is more attractive than HOLX's 17.4x.
| Metric | IVFINVO Fertility, I… | HOLXHologic, Inc. | NTRANatera, Inc. | INMDInMode Ltd. |
|---|---|---|---|---|
| Market CapShares × price | $2M | $17.0B | $27.5B | $884M |
| Enterprise ValueMkt cap + debt − cash | $12M | $17.6B | $26.7B | $595M |
| Trailing P/EPrice ÷ TTM EPS | -0.01x | 30.53x | -127.79x | 9.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.21x | — | 10.32x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | 0.98x |
| EV / EBITDAEnterprise value multiple | — | 17.39x | — | 6.91x |
| Price / SalesMarket cap ÷ Revenue | 0.37x | 4.14x | 11.94x | 2.39x |
| Price / BookPrice ÷ Book value/share | 0.01x | 3.43x | 15.51x | 1.34x |
| Price / FCFMarket cap ÷ FCF | — | 18.44x | 252.31x | 10.49x |
INMD leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
INMD leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
INMD delivers a 13.3% return on equity — every $100 of shareholder capital generates $13 in annual profit, vs $-5 for IVF. INMD carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to IVF's 0.78x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs INMD's 3/9, reflecting strong financial health.
| Metric | IVFINVO Fertility, I… | HOLXHologic, Inc. | NTRANatera, Inc. | INMDInMode Ltd. |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -4.7% | +11.0% | -15.1% | +13.3% |
| ROA (TTM)Return on assets | -99.6% | +6.1% | -10.4% | +11.8% |
| ROICReturn on invested capital | -42.2% | +9.4% | -36.1% | +13.5% |
| ROCEReturn on capital employed | -41.6% | +8.8% | -18.3% | +12.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 5 | 3 |
| Debt / EquityFinancial leverage | 0.78x | 0.52x | 0.13x | 0.02x |
| Net DebtTotal debt minus cash | $9M | $667M | -$862M | -$289M |
| Cash & Equiv.Liquid assets | $741,396 | $2.0B | $1.1B | $303M |
| Total DebtShort + long-term debt | $10M | $2.6B | $214M | $13M |
| Interest CoverageEBIT ÷ Interest expense | -27.64x | 8.00x | -34.29x | — |
INMD leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,442 today (with dividends reinvested), compared to $0 for IVF. Over the past 12 months, HOLX leads with a +35.3% total return vs IVF's -99.3%. The 3-year compound annual growth rate (CAGR) favors NTRA at 54.1% vs IVF's -94.4% — a key indicator of consistent wealth creation.
| Metric | IVFINVO Fertility, I… | HOLXHologic, Inc. | NTRANatera, Inc. | INMDInMode Ltd. |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -61.8% | +1.9% | -15.1% | -5.7% |
| 1-Year ReturnPast 12 months | -99.3% | +35.3% | +19.5% | -1.9% |
| 3-Year ReturnCumulative with dividends | -100.0% | -8.5% | +265.8% | -60.1% |
| 5-Year ReturnCumulative with dividends | -100.0% | +16.8% | +114.4% | -61.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | +124.3% | +1834.7% | +105.6% |
| CAGR (3Y)Annualised 3-year return | -94.4% | -2.9% | +54.1% | -26.4% |
NTRA leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.45 beta — it tends to amplify market swings less than IVF's 1.29 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs IVF's 0.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IVFINVO Fertility, I… | HOLXHologic, Inc. | NTRANatera, Inc. | INMDInMode Ltd. |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.29x | 0.45x | 1.17x | 1.00x |
| 52-Week HighHighest price in past year | $297.60 | $76.04 | $256.36 | $16.74 |
| 52-Week LowLowest price in past year | $1.61 | $53.62 | $131.81 | $12.72 |
| % of 52W HighCurrent price vs 52-week peak | +0.6% | +100.0% | +75.8% | +83.4% |
| RSI (14)Momentum oscillator 0–100 | 29.0 | 69.1 | 59.8 | 46.6 |
| Avg Volume (50D)Average daily shares traded | 50K | 10.3M | 1.4M | 815K |
HOLX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: HOLX as "Hold", NTRA as "Buy", INMD as "Hold". Consensus price targets imply 36.8% upside for NTRA (target: $266) vs 3.9% for HOLX (target: $79).
| Metric | IVFINVO Fertility, I… | HOLXHologic, Inc. | NTRANatera, Inc. | INMDInMode Ltd. |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Hold |
| Price TargetConsensus 12-month target | — | $79.00 | $265.63 | $17.00 |
| # AnalystsCovering analysts | — | 42 | 27 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.4% | 0.0% | +14.4% |
Insufficient data to determine a leader in this category.
Key Takeaway
INMD leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). NTRA leads in 1 (Total Returns).
Best OverallInMode Ltd. (INMD)Leads 3 of 6 categories
Loading custom metrics...
IVF vs HOLX vs NTRA vs INMD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is IVF or HOLX or NTRA or INMD a better buy right now?
For growth investors, INVO Fertility, Inc.
(IVF) is the stronger pick with 116. 3% revenue growth year-over-year, versus -6. 2% for InMode Ltd. (INMD). InMode Ltd. (INMD) offers the better valuation at 9. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Natera, Inc. (NTRA) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — IVF or HOLX or NTRA or INMD?
On trailing P/E, InMode Ltd.
(INMD) is the cheapest at 9. 8x versus Hologic, Inc. at 30. 5x. On forward P/E, InMode Ltd. is actually cheaper at 10. 3x.
03Which is the better long-term investment — IVF or HOLX or NTRA or INMD?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +114. 4%, compared to -100. 0% for INVO Fertility, Inc. (IVF). Over 10 years, the gap is even starker: NTRA returned +1835% versus IVF's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — IVF or HOLX or NTRA or INMD?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 45β versus INVO Fertility, Inc. 's 1. 29β — meaning IVF is approximately 184% more volatile than HOLX relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 78% for INVO Fertility, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — IVF or HOLX or NTRA or INMD?
By revenue growth (latest reported year), INVO Fertility, Inc.
(IVF) is pulling ahead at 116. 3% versus -6. 2% for InMode Ltd. (INMD). On earnings-per-share growth, the picture is similar: INVO Fertility, Inc. grew EPS 55. 2% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — IVF or HOLX or NTRA or INMD?
InMode Ltd.
(INMD) is the more profitable company, earning 25. 3% net margin versus -139. 3% for INVO Fertility, Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus -124. 4% for IVF. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is IVF or HOLX or NTRA or INMD more undervalued right now?
On forward earnings alone, InMode Ltd.
(INMD) trades at 10. 3x forward P/E versus 17. 2x for Hologic, Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NTRA: 36. 8% to $265. 63.
08Which pays a better dividend — IVF or HOLX or NTRA or INMD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is IVF or HOLX or NTRA or INMD better for a retirement portfolio?
For long-horizon retirement investors, Natera, Inc.
(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 17), +1835% 10Y return). Both have compounded well over 10 years (NTRA: +1835%, IVF: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between IVF and HOLX and NTRA and INMD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: IVF is a small-cap high-growth stock; HOLX is a mid-cap quality compounder stock; NTRA is a mid-cap high-growth stock; INMD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(IVF: 22.6% · HOLX: 2.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.